Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Overview
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
Full Title of Study: “Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: April 2009
Interventions
- Other: There is no intervention in this study.
- This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Arms, Groups and Cohorts
- There is no intervention in this study
- This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Clinical Trial Outcome Measures
Primary Measures
- To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.
- Time Frame: duration of study
Secondary Measures
- To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.
- Time Frame: duration of study
Participating in This Clinical Trial
Inclusion Criteria
- Subjects diagnosed at study visit or within 3 months of visit with OH – OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma) Exclusion Criteria:
- No prior treatment for OH or OAG – No prior ocular surgery or history of ocular trauma
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Pfizer CT.gov Call Center, Study Director, Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.